G
Graeme J. Moffat
Researcher at Syngenta
Publications - 3
Citations - 703
Graeme J. Moffat is an academic researcher from Syngenta. The author has contributed to research in topics: Glutathione S-transferase & Glutathione. The author has an hindex of 3, co-authored 3 publications receiving 673 citations.
Papers
More filters
Journal ArticleDOI
Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice.
Simon A. Chanas,Qing Jiang,Michael McMahon,Gail K. McWalter,Lesley I. McLellan,Clifford R. Elcombe,Colin J. Henderson,C. Roland Wolf,Graeme J. Moffat,Ken Itoh,Masayuki Yamamoto,John D. Hayes +11 more
TL;DR: The increased sensitivity of Nrf2(-/-) mice to xenobiotics can be partly attributed to a loss in constitutive expression of multiple GSH-dependent enzymes, which causes a reduction in intrinsic detoxification capacity in the KO animal and probably accounts for their failure to adapt to chronic exposure to chemical and oxidative stress.
Journal Article
Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin B1-aldehyde reductase, the glutathione S-transferase A5 and P1 subunits, and NAD(P)H:quinone oxidoreductase in rat liver
Vincent P. Kelly,Elizabeth M. Ellis,Margaret M. Manson,Simon A. Chanas,Graeme J. Moffat,Ronald McLeod,David J. Judah,Gordon E. Neal,John D. Hayes +8 more
TL;DR: The data suggest that consumption of a CMRN-containing diet provides substantial protection against the initiation of AFB1 hepatocarcinogenesis in the rat, and the ability of the benzopyrone to inhibit either AFB1-initiated preneoplastic nodules or AFB1- initiated liver tumors was investigated.
Journal ArticleDOI
The practical application of three validated in vitro embryotoxicity tests. The report and recommendations of an ECVAM/ZEBET workshop (ECVAM workshop 57).
Horst Spielmann,Andrea Seiler,Susanne Bremer,Lars Hareng,Thomas Hartung,H.J. Ahr,Elaine M. Faustman,Ulla Haas,Graeme J. Moffat,Heinz Nau,Philippe Vanparys,Aldert H. Piersma,Juan Riego Sintes,Jane Stuart +13 more
TL;DR: The ECVAM Scientific Advisory Committee (ESAC) concluded from the results that the three in vitro embryotoxicity tests had been sufficiently validated and could be applied to the assessment of the embryotoxic potential of drugs and other chemicals.